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Abstract
Metformin has been known to the mankind for centuries. Metformin is the first line of drug of choice for the treatment of 
type 2 diabetes. Initial pharmaceutical therapy was for treating the frequent urinal problem which is a primary manifestation 
of diabetes. At the time of writing, metformin as an intervention is looked into for cardiovascular risks, polycystic ovary 
syndrome and breast cancer. Annual demand for Metformin is 23,000 Metric tons per annum. Nano Drug Delivery Systems 
(NDDS) has embarked into Metformin controlled and targeted delivery for breast cancer, pancreatic cancer and non-small 
cell lung cancer. Clinical estimation of the biological fluids by the FDA approved diagnostic laboratories use LC-MS/MS 
where blood samples estimate Metformin as an intact molecule easing the pressure of clinical trials result. Metformin 
was manufactured by a less known and low profile Aoron pharmaceutical, France not aware of the block buster drug 
hence the potential of technology development start-ups can neither be underwritten nor underestimated even when 
there is a very high rate (~90%) of failed biotech/biomed start-up ventures. The bloom of the French lilac (metformin) to 
blossom and flower for the cure of breast cancer by convergence revolution initiative with the integration of academia, 
hospital, technology business incubator, multinational corporation with the deliverance of a start-up company
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1. Introduction
Metformin is the oral antihyperglycaemic drug of choice 
for type 2 diabetes mellitus treatment. This drug is 
unique from other oral  antihyperglycaemic agents in the 
sense that this drug of choice not only subdues hepatic 
glucose production, reduces the intestinal glucose 
absorption and to a further extent improves  insulin 
sensitivity. This drug proves further uniqueness in not 
causing hyperinsulinaemia. In-vitro and in-vivo studies 
suggest for a direct connectivity between diabetes and 
oncological manifestations. This review works and 
moves in the direction to depict metformin being an oral 
antihyperglycaemic drug at some point of time may act 
also as an anticancer drug wherein this combinatorial 
property is not exhibited by other antihyperglycaemic 
drugs. In the scope of this article, convergence revolution 
initiates the integration (rather than as collaboration) of 
chemical engineering, biotechnology, medicine with the 
aid of multinational corporation, hospital, technology 
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business incubator, philanthropic foundation and start-
up company with the best ability to forge a new innovative 
initiative path for the technology development for the 
cure of breast cancer. This is very much depicted by 
the authors of this article who are chemical engineers, 
bioengineers, design engineers, biotechnologists, design 
engineer medical practitioners (both specialized and 
budding), philanthropists, technology developers and 
big data analysts. More integration from regulators, 
onco-psychologists and federal funders would further 
accelerate for the cure of breast cancer with the classical 
example of cancer moonshot initiative.
2. History
Medieval Europe used Galega officinalis Lin possessing 
white, blue or purple flowers as an extract to be used as an 
herbal medicine. Chemical analysis revealed guanidine 
and associated compounds were found to be abundant 
in the extracts of Galega officinalis Lin dating back to 
mid-1800s. The plant is also called as goat’s rue, French 
lilac (Figure 1), Spanish sanfoin and false indigo. 
Fig. 1.  Bloom of French Lilac. 
In 1918, belonging to a class of drugs that has been 
part of the human apothecary for 500 years, guanidine 
Fig. 3.  Panacea action of Metformin.
Fig. 2.  Chemical reaction of Metformin production.
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was reportedly1 reduced blood glucose levels in animal 
models. The chemical itself was first reported in 1922 by 
the Dublin chemists Emil Werner and James Bell2,3. 
Metformin was rediscovered in the search for 
antimalarial agents in the 1940s and, during clinical 
tests, proved useful to treat influenza when it sometimes 
lowered blood glucose. 
First report on the clinical use of metformin for 
the treatment of diabetes was in 1957 by the French 
physician Jean Sterne. A French company called 
Aron Laboratories, situated in Suresnes, Paris, France 
granted permission Jean Sterne to carry out his clinical 
trials experiments. Sterne selected dimethylbiguanide 
(metformin) for clinical development and proposed the 
name ‘Glucophage’ (glucose eater)4. 
Jean Sterne’s scientific temperament, administrative 
mettle with sharp enquiring mind facilitated the pragmatic 
prodigious experimentation appended by his perceptive 
clinical sixth sense transformed the blood-glucose 
diminutive potential of metformin into a therapeutic 
commercial success culminating him into a visionary. 
3. United States Scenario
After several decades only United States of America was 
able to use metformin after FDA approved metformin 
in 1994, Bristol-Myers Squibb has applied (Application 
number: 020357/S010) for metformin5. An important 
clinical trials of metformin was carried out in 1995 in 
USA immediately after the FDA approval6.
Currently it is estimated that approximately, 37,000 
metric tons of metformin is manufactured and mostly in 
FDA approved pharmaceutical companies in India. 
4. Clinico Pharmacology
4.1 Chemical Synthesis
Synthesis of metformin dates back to 1920s (Figure 
2), when metformin was synthesized using a single 
step process involving the reaction of dimethylamine 
hydrochloride and 2-cyanoguanidine (dicyandiamide) 
upon heating at increased temperature levels. Equimolar 
quantities of dimethylamine and 2-cyanoguanidine 
are made into a solution using toluene as the 
solvent, with gradual addition equimolar amount 
of hydrogen chloride the solution starts boiling and 
upon cooling, precipitation occurs. The precipitate 
formed is N, N-dimethylimidodicarbonimidic 
diamide hydrochloride with a 96% yield which is 
Metformin hydrochloride2,3. Metformin hydrochloride 
(IUPAC: N, N-dimethylimidodicarbonimidic 
diamide hydrochloride) is the Active Pharmaceutical 
Ingredient (API) of the finished product of the oral 
antihyperglycemic drug used for the treatment and 
management of type 2-diabetes.  
5. Estimation of Metformin in Bio-
logical Fluids
Sensitive and specific methods for analysis of biguanides 
in biological fluids7,8 are essential to an evaluation of 
their safety and efficacy. Metformin can be determined 
in biological fluids by various methods. Early assays were 
based on spectrophotometry which has a low specificity 
and sensitivity.
Mass spectrometry has been developed but the 
equipment required is not generally available in a 
routine analytical laboratory. High performance liquid 
chromatography9–11 is now considered as the method of 
choice for the assay of metformin because of its simplicity, 
rapidity, high specificity, reproducibility and sensitivity. 
Quite recently the plasma concentration of metformin 
is being determined using Liquid chromatography 
tandem mass spectroscopy (LC–MS/MS System)12. 
Other methods for estimation of metformin from blood 
plasma includes Ion pair liquid chromatography13 and 
HPLC with spectrophotometric detection14.
6. Pharmacological Actions
Metformin is found to affect multiple key processes 
related to cell growth, proliferation, and survival. 
Metformin which is a panacea drug (Figure 3) has the 
potential to treat myriads of diseases which are type 2 
diabetes mellitus, cardiovascular risks, life extension for 
pancreatic cancer patients, poly cystic ovarian syndrome, 
oncogenic tumors and now on the clinical trials for 
breast cancer. 
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6.1 Diabetes Mellitus
For type 2 diabetes for more than half a century, the drug 
of choice is metformin, for it is an orally administered 
drug in the form of tablets. The well-known trade 
name is called as Glucophage™. The implicating factors 
associated with the manifestation of the type 2 diabetes 
are well counteracted by the panacea drug Metformin. 
This drug acts with maximum efficacy on the levels of 
glucose and lipids in blood. To be more specific with 
a scientific representation, the protective effects make 
this drug of choice to be more efficient in terms of the 
adverse metabolic side effects of the other drugs which 
results often in obesity. Under physiological conditions, 
if cells become insulin-resistant, they no longer 
respond to insulin release by absorbing glucose. More 
glucose stays in the bloodstream, a condition known as 
hyperglycemia. Metformin improves insulin sensitivity 
in the peripheral tissues and thereby controls excessive 
glucose production. Metformin has been prescribed to 
overcome obesity15–18.
6.2 Polycystic Ovarian Syndrome (PCOS)
Metformin treats PCOS, major physiological 
manifestation of this syndrome being obesity and 
infertility. PCOS19,20  is linked with higher levels of 
circulating insulin, which is characteristic in  type 2 
diabetes. Several endocrine and metabolic physiological 
abnormalities like insulin resistance and systolic 
blood pressure have been countermanded by the oral 
administration of metformin. Insulin resistance occurs 
most often in people who have a family history of obesity 
and women who have PCOS. Sedentary lifestyle also 
contributes to insulin resistance. People with insulin 
resistance often gain weight. High insulin levels can 
increase hunger, people with high insulin levels gain 
weight. Since metformin is a drug which lowers insulin 
results in an improved weight loss. Metformin along 
with a structured lifestyle intervention21–23 improves 
insulin sensitivity through increasing muscle glucose 
uptake and use. Obstetrics and gynecological conditions 
like irregular menstrual cycles and delayed pregnancy 
has been reversed at the doses of 500 mg to 850 mg of 
metformin thrice a day.
6.3 Cardio Vascular Risks
Metformin treats cardiovascular risks in Diabetic 
as well as non-diabetic individuals. Several cardio 
vascular associated diseases like hypertension and 
hypofibrinolysis could be treated using metformin24. 
Metabolic abnormalities consociated with cardiovascular 
diseases in particular visceral obesity is also being 
tackled by metformin. These associated factors conduce 
the enhanced cardiovascular risks associated with 
patients suffering from type 2 diabetes. Thereby, regular 
medications with metformin reduce cardiovascular risk.
6.4 Breast Cancer
In the in-vitro breast cancer cell lines experimentations, 
hormone receptor subtypes of breast cancer, AMPK 
stimulation25–27 by metformin leads to total cell growth 
inhibition in Estrogen Receptor (ER)-positive in-vitro cell 
lines. In terms of ER-negative cell lines partial inhibition 
is observed. The drug’s effects on these processes stem 
from both metabolic and intracellular-signaling activity. 
The action of metformin on cancer cell proliferation is 
associated with AMPK activation, reduced Mammalian 
Target of Rapamycin (mTOR) signaling and protein 
synthesis, as well as a variety of other responses 
including decreased epidermal growth factor receptor 
(EGFR), Src, and mitogen-activated protein kinase 
(MAPK) activation, decreased expression of cyclins, and 
increased expression of p2728,29. Metformin has been 
found to induce apoptosis in certain cell lines derived 
from endometrial cancers, glioma, and triple negative 
breast tumors. Therefore from these mechanisms it is 
quite evident that metformin prevents cancer30,31. The 
panacea drug Metformin is still under clinical trials for 
breast cancer.
6.5 Global Manufacturing Scenario
Global population of has now reached 7.5 billion of 
which 8.5% are living with diabetes approximately 
420 million are in need of antihyperglycemic drug. As 
per FDA’s Drug Master File (DMF) filings there are 18 
leading global metformin producers. The average plant 
capacity of each producer would be about 3800 tons per 
year. Currently it is estimated that approximately, 37,000 
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metric tons of metformin is manufactured annually and 
mostly in FDA approved companies in India.
The generic Metformin is manufactured by 129 
companies with 258 Brands of Generics of Metformin. 
Key API global manufacturers are: Bristol-Mayers 
Squibb, Shouguang Fukang Pharmaceutical, Harman 
Finochem, Vistin Pharma, Cr Double-Crane, Keyuan 
Pharmaceutical, Farmhispania Group, Shijiazhuang 
Polee Pharmaceutical, Merck Sante and Aarti Drugs. 
6.6 Mechanism of Action in Anticancer 
Activity
At the time of working on this report writing, there has 
not been a substantial scientific evidence of molecular 
mechanistic pathway of anticancer activity of metformin. 
Several plausible molecular mechanistic pathway has 
been reported for metformin’s antineoplastic action on 
the basis several in vitro studies.
Several proposed mechanisms are: 
•	 Decreased LKB1 thereby a reduction AMPK levels 
resulting in mTOR activation followed by decreased 
S6 kinase activation32
•	 Increased expression of REDD1 resulting in 
diminished mTOR activation followed by decreased 
S6 kinase activation33
•	 Inhibition of STAT3 facilitating and enhancing 
apoptosis induction34
•	 Alteration of the expression oncological associated 
miRNAs namely, miRNA let7A and miRNA- 18135
Metformin affects cell signaling pathways directly or 
indirectly at multiple points. For this reason, the drug 
may be useful against numerous cancer types. 
As it has been mentioned, metformin acting directly 
on cancer cells have been reported where the chemical 
moiety acts on the mitochondrial respiration resulting 
in the stimulation of AMP-Activated Protein Kinase 
(AMPK). This stimulation action cascades to the 
activation of liver kinase B1 (LKB1)36. The elemental 
upstream kinase of AMPK is being, LKB1. For regular 
maintenance of energy homeostasis in the cellular 
environment AMPK and LKB137 are the necessary 
elements for the normal physiological activities.  
The other mechanism being an indirect action more 
on the host cell metabolism where reduced activity of 
hepatic gluconeogenesis (AMPK mediated) resulting 
in lowered circulating insulin levels. Involvement of 
lowered activation of PI3K pathway mediated by insulin/
IGF-1 receptor38 has also been reported. 
Mammalian target rapamycin complex 1 (mTORC1) 
suppression is mainly associated with the anticancer 
molecular action of metformin. Metabolism, growth and 
proliferation of cancer cells are the pivotal roles played 
by the mTOR. It is observed that mTORC1 pathway is 
inhibited by metformin. 
Metformin inhibits Mtor pathway both by dependent 
and as well as independent of AMP-activated protein 
kinase activation as suggested by evidences. Tuberous 
sclerosis complex protein 2 (TSC2)39 is phosphorylated 
by AMPK, which inhibits Mtorc. This inhibition of 
Mtorc leads to decreased activities of protein synthesis 
and finally at the macro level, the cell growth.  Since 
AMPK directly phosphorylates Mtor, inhibition of Mtor 
could be independent on TSC239. Metformin directs the 
upregulation of AMP-activated protein kinase. This is 
the key molecule in the regulation of glucose and insulin 
levels. It also plays a role as an inhibitor of mTOR. 
Metformin acts on the hepatic cells whereby 
decreasing the levels of glucose produced by the hepatic 
cellular action resulting in the bloodstream levels and 
also on the cellular uptake of insulin40. These molecular 
actions trigger a cascade of mechanisms at the molecular 
level leading to the down regulation of the Ras/Raf/
MEK/ERK. Also it triggers PI3K/AKT/mTOR signaling 
pathways41. Any one or both of the above mentioned 
pathways are regularly activated in different types of 
carcinogenesis. 
Autophagy is activated by AMPK directly and 
indirectly activating ULK1. AMPK also appears to 
stimulate mitochondrial biogenesis by regulating 
PGC1α (a mitochondrial stimulator of metformin 
biogenesis) which in turn promotes gene transcription 
in mitochondria42.
The plausible mechanism pathways hypothized can 
give the federal funding agencies to give a thinking 
to approve and fund the technology development in 
animal models to increase and improve the efficacy of 
metformin as an antineoplastic drug. 
6.7 Controlled Release
A novel drug delivery nanocomposite film based system 
made of poly(ethylene glycol)-blockpoly(propylene 
glycol)-block-poly(ethylene glycol) (BP) polymers 
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embedded with metformin and MCM-41 or MCM-41-
APS (APS = Aminopropylsilane) nanoparticles (NPs) was 
produced. A short burst release was observed by one day 
(22-24 hours) then a sustained controlled release for 15 
days was observed. The film containing 4%MCM-41-APS 
NPs had the slowest release (45% release after 15 days)43. 
Co-encapsulation of cisplatin and metformin using 
Polyglutamic Acid (PGA) was synthesized. A cationic 
polymeric agent namely Polymeric Metformin (polymet) 
was used for the treatment of Non-Small Cell Lung 
Cancer (NSCLC). A cationic liposomes containing of 
DOTAP44 (2,3-Dioleoyloxy-propyl)-trimethylammonium/
Cholesterol/DSPE-PEG-anisamide aminoethyl was used 
as the stabilizing agent. A synergistic action was observed 
whereby the tumor growth was suppressed by the mechanism 
of apoptosis NSCLC H460 tumor-bearing mice. 
Fig. 4.  Anticancer activity of metformin.
Table 1:  List of clinical trials of metformin for breast cancer therapy
ID Intervention Phase Dosage (mg) Duration (weeks) Outcome (primary) 
NCT00909506 Metformin
Placebo
II 500 mg 
(once a day)
1-2 
3-24
3-24
Weight loss
Placebo pill 
(every morning)
Metformin 500 mg 
(every evening)
Escalation study:
Metformin 500 mg 
(every morning and evening)
NCT01266486 Metformin
(Extended 
release)
II Extended release Metformin 
(1500mg once daily)
2-3 Biomarkers:
S6K, 
4E-BP-1, 
AMPK
NCT00897884 Metformin NA Metformin
(500 mg) 
Thrice daily
2-3 Cell proliferation 
reduction
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Ionic-gelation method was used for the synthesis 
of O-carboxymethyl chitosan (O-CMC) nanoparticles 
embedded with metformin. A therapy for pancreatic cancer 
was tried upon. Metformin embedded nanoparticles 
exhibited higher cytotoxicity on pancreatic cancer cell 
lines (MiaPaCa-2)45 in comparison with normal cell lines 
(L929) resulting in targeted delivery showing a prospective 
aspect of the synthesized nanoparticles. 
Hyaluronic acid- Au nanoparticles embedded with 
metformin were synthesized for a potential therapy for 
liver cancer. Active targeting principle was exhibited 
for the apoptosis liver cancer (HepG2 cells)46. In terms 
of the dosage lower amount the nanoformulation was 
sufficient for 50% inhibition (IC50) when compared to 
the free metformin. 
A different technique of electrospinning called 
emulsion electrospinning was used for the production 
of nanofiber scaffolds embedded with metformin 
hydrochloride. The nanocarriers are made of poly 
(ε-caprolactone) (PCL) and Poly (3- Hydroxybutyric 
Acid-Co-3-Hydroxyvaleric Acid) (PHBV)47 organic 
biocompatible polymers. PCL nanocarriers were 
compared with PHBV nanocarriers for their controlled 
drug release efficiency. It has been reported that PCL 
nanofiber scaffold was able to deliver at a controlled way 
over a period of time and also with lowest burst release.  
Metformin surface modified cellulose nanofibers 
(Met-Cel-NFs) were successfully prepared by attachment 
of metformin on the surface of cellulose nanofibers 
through electrostatic inter-action. 
Gels composed of cellulose based nanofibers 
embedded with metformin were manufactured as a 
potential anti-metastasis novel nano drug delivery 
system for the prevention of human melanoma cancer 
metastasis. Mode of administration of this novel gel 
is quite easy in the sense Met-Cel-NFs gel48 could be 
sterilized easily and injected around or into the tumor. 
6.8 Clinical Trials
6.8.1 First Clinical Trial
First clinical trials for metformin were carried out in 
Paris in 1957 for type 2 diabetes. Earlier years, metformin 
was called as glucophage (‘glucose eater’). Clinical trials 
were so successful in the way blood glucose with type 2 
diabetes was lowered but unaltered in the subjects who 
were non-diabetic. 
A report published in 2005 reported the use of 
metformin decreased the risk of cancer by 23% 49. Moving 
forward, in 2012, substantial evidence was obtained with 
an insight for metformin as an antineoplastic agent50 
(Figure 4). 
Progression free survival (PFS), Relapse/Recurrence 
Free Survival (RFS), and Metastasis-Free Survival 
(MFS), combined together called as patient overall 
disease-free survival (OS) should be the major outcome 
of a clinical trial. FDA has not yet approved the use 
of metformin as a single chemotherapeutic agent for 
breast cancer but very much of a possibility in the near 
future. Insulin entered the commercial market nearly the 
same time when metformin was in the final stages and 
phase of clinical trials which really masked the greater 
panacea drug potential of metformin. Insulin was never 
tried as a stand-alone generic or even as an adjuvant 
for any other disease apart from diabetes but for good 
metformin is in the clinical trials for poly cystic ovary 
syndrome, anti-ageing, cardio vascular intervention and 
onco tumorogenesis especially breast cancer. Clinical 
trials in the direction of diabetic subjects suffering from 
breast cancer for which medication regimen is quite 
challenging when compared to non-diabetic subjects 
with breast cancer, metformin may become a panacea 
drug as we are getting very prospective clinical trials 
endpoint results. It is a well-known fact that elevated 
levels of glycolysis is observed in cancer patients in 
the scientific terms metabolism, glucose regulation 
and inflammation influence cancer manifestation 
outcomes especially breast cancer. Planning a clinical 
trial using metformin, metformin with a Breast Cancer 
Drug (BCD), only BCD and insulin with BCD should 
pave way for better understanding. By including two 
different categories of clinical trials breast cancer patient 
volunteers namely breast cancer patients with diabetes 
and breast cancer patients free of diabetes would provide 
a very informative insight for the panacea action of 
metformin for breast cancer. 
As of date, there are six clinical trials (NCT0089788451, 
NCT0126648652, NCT0165050653, NCT0090950654, 
NCT0188501355, NCT0065956856) that have been 
completed using metformin as an intervention for breast 
cancer (Table 1).
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Of which three51–53of the clinical trials have used 
metformin as a single intervention of choice. With 
supporting evidences based on several clinical trials, 
it is practically evident that metformin is used as a 
chemotherapeutic agent for tumor growth suppression 
(NCT0131023157, NCT0093057958) on breast cancer 
patients. With the advent of convergence revolution59 
future of oncological interventions belongs to localized 
chemotherapy by the use nanocarriers60 using 
biocompatibe polymers61, hence metformin would be 
for more number of further clinical trials.
7. Conclusion
Principally by scientific evidence metformin molecular 
mechanistic action is by decreasing the glucose levels 
produced by the liver, reducing the bloodstream level 
and cascading by cellular uptake of insulin. In turn, the 
reduced insulin stimulation results in reduced activation 
of insulin receptors on cell membranes, triggering a 
cascade of intracellular molecular effects on various 
signal pathways. These pathways are often activated 
in many types of cancer cells. Cancer patient being 
treated for diabetes dwell with comorbidity ending up 
in psychological depression and financial ruin. Based on 
the in-vitro and in-vivo results there are a great potential 
to prescribe metformin as a combinatorial therapeutic 
agent. At the translational research level, in vitro and 
in vivo studies have supported the use of metformin in 
several cancer types and, along with tumor specimen 
biomarker studies, have begun to elucidate the molecular 
mechanisms of metformin’s action. The bloom of the 
French lilac may be realized to blossom and flower in 
a new direction in the therapy for not only diabetes 
mellitus but also cardiovascular risks, polycystic ovarian 
syndrome, oncogenic tumors and of course for the cure 
of breast cancer. 
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